Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Immunotherapy Could Still Play a Role After Progression in Patients With RCC

March 2nd 2022

Moshe Ornstein, MD, MA, discusses trials exploring second-line immunotherapy in patients who have progressed on immunotherapy, plus key clinical trial data on kidney cancer and other pressing areas of need for research in renal cell carcinoma.

Trametinib Represents a New Standard-of-Care Option in Recurrent Low-Grade Serous Ovarian Carcinoma

March 1st 2022

The MEK inhibitor trametinib reduced the risk of disease progression or death by 52% compared with current standard-of-care therapies in patients with relapsed or persistent low-grade serous ovarian carcinoma, making it the potential new SOC for this patient population.

Treatment and Sequencing Options Continue to Evolve in Relapsed/Refractory DLBCL

February 28th 2022

The emergence of novel agents, including CAR T-cell therapies and antibody-drug conjugates, plus existing options such as chemoimmunotherapy and bone-marrow transplant, have combined to raise questions about the sequencing of these treatments in patients with diffuse large B-cell lymphoma.

Neoadjuvant Atezolizumab/Chemo Shows Encouraging Efficacy in Muscle-Invasive Bladder Cancer

February 24th 2022

The addition of atezolizumab to neoadjuvant gemcitabine and cisplatin generated a high rate of non–muscle-invasive downstaging following radical cystectomy, which correlated with improved relapse-free survival and overall survival in patients with muscle-invasive bladder cancer, according to data from a phase 2 trial.

Addition of Bevacizumab to Ixabepilone Is Effective, Tolerable in Platinum-Resistant Ovarian Cancer

February 23rd 2022

The combination of ixabepilone and bevacizumab significantly improved progression-free survival vs ixabepilone alone in the treatment of platinum-resistant ovarian cancer, according to data from the phase 2 trial published in the British Journal of Cancer.

Niraparib Demonstrates Antitumor Activity in Heavily Pretreated mCRPC With BRCA Mutations

February 23rd 2022

The PARP inhibitor niraparib elicited a meaningful overall response rate in patients with heavily pretreated metastatic castration-resistant prostate cancer and DNA repair gene defects, particularly those with BRCA alterations.

FDA Grants Orphan Drug Designation to CT103A for Relapsed/Refractory Myeloma

February 21st 2022

The FDA has granted an orphan drug designation to the investigational anti-BCMA CAR T-cell therapy CT103A for use as a potential therapeutic option in patients relapsed/refractory multiple myeloma.

Lack of Access to Screening Leads to More Advanced Cancer in Socially and Economically Challenged Populations

February 21st 2022

Many Americans, particularly those in communities of color or socially and economically challenged populations, are presenting with advanced-stage disease, enduring aggressive treatment, and dying from cancers that should be detected early.

Addition of Lenvatinib to Pembrolizumab Fails to Improve Survival in Advanced Urothelial Carcinoma

February 18th 2022

The combination of lenvatinib and pembrolizumab elicited comparable antitumor activity compared with placebo plus pembrolizumab as frontline therapy in patients with advanced urothelial carcinoma who were ineligible for platinum-based chemotherapy, according to data from LEAP-011.

Daily Aspirin Does Not Prevent Recurrence in High-Risk, HER2-Negative Breast Cancer

February 16th 2022

The administration of daily aspirin did not improve invasive disease-free survival in patients with high-risk, HER2-negative breast cancer.

Frontline Ibrutinib/Rituximab Produced Meaningful Response Rates in Indolent MCL

February 11th 2022

The combination of ibrutinib plus rituximab generated a high rate of complete response and undetectable minimal residual disease when used in the frontline treatment of patients with indolent clinical forms of mantle cell lymphoma, allowing for treatment interruption in most responders.

Patients With HER2+ Breast Cancer Who Achieve pCR With Neoadjuvant HER2-Targeted Therapy Have Better DFS, OS

February 9th 2022

Patients with HER2-positive, early-stage breast cancer who achieved a pathologic complete response after receiving HER2-targeted therapy experienced better outcomes in terms of disease-free survival and overall survival vs those who did not, according to data from a real-world study.

Doctors Must Stand at Frontlines in Fight Against Disparities in Screening, Treatment of Thoracic Malignancies

February 8th 2022

Health care disparities remain a major issue in cancer care, and factors contributing to this inequality stretch far beyond access to clinical care.

Imatinib/Binimetinib Combo Shows Efficacy With Manageable Safety in Treatment-Naïve Advanced GIST

February 8th 2022

The combination of the TKI inhibitor imatinib and the MEK inhibitor binimetinib elicited encouraging responses in patients with treatment-naïve advanced gastrointestinal stromal tumors.

Teclistamab/Daratumumab Combo Elicits Encouraging Responses in Relapsed/Refractory Myeloma

February 7th 2022

The subcutaneous combination of the BCMA-targeting bispecific antibody teclistamab and daratumumab produced promising preliminary efficacy and favorable tolerability in heavily pretreated patients with relapsed or refractory multiple myeloma, according to results from the phase 1b TRIMM-2 trial.

Nivolumab/Ipilimumab Followed by Dabrafenib/Trametinib Improves OS in BRAF V600–Mutated Advanced Melanoma

February 3rd 2022

Frontline administration of the checkpoint inhibitors ipilimumab plus nivolumab followed by the targeted agents dabrafenib plus trametinib improved overall survival in patients with BRAF V600–mutant melanoma vs the reverse sequence of combinations, according to data from the phase 3 DREAMseq trial presented during the ASCO Virtual Plenary Series.

Secondary Cytoreductive Surgery Requires Careful Selection in Recurrent Ovarian Cancer

January 31st 2022

Amer Karam, MD, discusses the role of secondary cytoreductive surgery in ovarian cancer and the need for careful patient selection, plus the results from 3 clinical trials and the key differences between these efforts.

Tivozanib/Durvalumab Combo Demonstrates Early Efficacy, Tolerability in Advanced HCC

January 25th 2022

The combination of tivozanib and durvalumab showcased early efficacy with a manageable safety profile in patients with previously untreated advanced hepatocellular carcinoma.

Long-Term Data Confirm Benefit of Erdafitinib in FGFR-Mutated Urothelial Carcinoma

January 25th 2022

The FGFR TKI erdafitinib continued to provide consistent clinical benefits with a manageable safety profile when used in the second-line treatment of patients with locally advanced or metastatic urothelial carcinoma harboring FGFR alterations.

Frontline Pembrolizumab Monotherapy, Plus Chemo Shows Mixed OS Findings in PD-L1+ Gastric/GEJ Adenocarcinoma

January 20th 2022

Although pembrolizumab monotherapy showed noninferiority to chemotherapy for overall survival in patients with advanced gastric or gastroesophageal junction adenocarcinoma and a PD-L1 combined positive score of 1 or higher, and a clinically meaningful benefit over chemotherapy in those with a CPS of 10 or higher, pembrolizumab plus chemotherapy failed to show superiority over chemotherapy alone in either subset.